[go: up one dir, main page]

WO2008103849A3 - Methods and compounds for lymphoma cell detection and isolation - Google Patents

Methods and compounds for lymphoma cell detection and isolation Download PDF

Info

Publication number
WO2008103849A3
WO2008103849A3 PCT/US2008/054613 US2008054613W WO2008103849A3 WO 2008103849 A3 WO2008103849 A3 WO 2008103849A3 US 2008054613 W US2008054613 W US 2008054613W WO 2008103849 A3 WO2008103849 A3 WO 2008103849A3
Authority
WO
WIPO (PCT)
Prior art keywords
ror
isolation
compounds
methods
sera
Prior art date
Application number
PCT/US2008/054613
Other languages
French (fr)
Other versions
WO2008103849A4 (en
WO2008103849A2 (en
Inventor
Thomas J Kipps
Tetsuya Fukuda
Tomoyuki Endo
Original Assignee
Univ California
Thomas J Kipps
Tetsuya Fukuda
Tomoyuki Endo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/709,917 external-priority patent/US20070207510A1/en
Application filed by Univ California, Thomas J Kipps, Tetsuya Fukuda, Tomoyuki Endo filed Critical Univ California
Publication of WO2008103849A2 publication Critical patent/WO2008103849A2/en
Publication of WO2008103849A3 publication Critical patent/WO2008103849A3/en
Publication of WO2008103849A4 publication Critical patent/WO2008103849A4/en
Priority to US12/545,731 priority Critical patent/US8212009B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Compositions comprising a purified and/or isolated antibody, humanized antibodies, precipitates and anti-sera that specifically bind to or are otherwise directed against ROR-1 protein. The compositions may be used for detecting ROR-1 in a sample from a subject that is suspected or known to contain cancer cells. The ROR-1 antibodies are especially useful in identifying and treating lymphomas and ademocarcinomas. Vaccines and related methods for protecting a subject against diseases that involve expression of ROR-1 are also provided, as are human anti-sera effective in abrogating interactions between Wnt5a protein and ROR-1 that contribute to the survival of certain cancer cells, such as CLL cells.
PCT/US2008/054613 2005-10-28 2008-02-21 Methods and compounds for lymphoma cell detection and isolation WO2008103849A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/545,731 US8212009B2 (en) 2005-10-28 2009-08-21 Methods and compounds for lymphoma cell detection and isolation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/709,917 US20070207510A1 (en) 2005-10-28 2007-02-21 Methods and compounds for lymphoma cell detection and isolation
US11/709,917 2007-02-21
US97181807P 2007-09-12 2007-09-12
US60/971,818 2007-09-12

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2006/042689 Continuation-In-Part WO2007051077A2 (en) 2005-10-28 2006-10-30 Methods and compounds for lymphoma cell detection and isolation
US11/709,917 Continuation US20070207510A1 (en) 2005-10-28 2007-02-21 Methods and compounds for lymphoma cell detection and isolation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/545,731 Continuation-In-Part US8212009B2 (en) 2005-10-28 2009-08-21 Methods and compounds for lymphoma cell detection and isolation

Publications (3)

Publication Number Publication Date
WO2008103849A2 WO2008103849A2 (en) 2008-08-28
WO2008103849A3 true WO2008103849A3 (en) 2008-10-23
WO2008103849A4 WO2008103849A4 (en) 2009-01-22

Family

ID=39710749

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/054613 WO2008103849A2 (en) 2005-10-28 2008-02-21 Methods and compounds for lymphoma cell detection and isolation

Country Status (1)

Country Link
WO (1) WO2008103849A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9523695B2 (en) 2011-01-14 2016-12-20 The Regents Of The University Of California Therapeutic antibodies against ROR-1 protein and methods for use of same
US9938350B2 (en) 2010-06-15 2018-04-10 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
US10344096B2 (en) 2012-08-24 2019-07-09 The Regents Of The University Of California Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
US10688181B2 (en) 2016-06-27 2020-06-23 The Regents Of The University Of California Cancer treatment combinations

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9316646B2 (en) 2009-04-23 2016-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ROR1 antibodies
US8877199B2 (en) 2009-05-15 2014-11-04 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services B cell surface reactive antibodies
US20120282177A1 (en) * 2009-11-02 2012-11-08 Christian Rohlff ROR1 as Therapeutic and Diagnostic Target
WO2011079902A2 (en) 2009-12-18 2011-07-07 Biolnvent International Ab Biological materials and uses thereof
GB2476293A (en) * 2009-12-18 2011-06-22 Biolnvent Internat Ab Therapeutic inhibition of ROR-1
US9228023B2 (en) 2010-10-01 2016-01-05 Oxford Biotherapeutics Ltd. Anti-ROR1 antibodies and methods of use for treatment of cancer
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
US11952421B2 (en) 2014-10-09 2024-04-09 Bristol-Myers Squibb Company Bispecific antibodies against CD3EPSILON and ROR1
HK1254836A1 (en) 2015-10-30 2019-07-26 Nbe-Therapeutics Ag Anti-ror1 antibodies
BR112018014615A2 (en) 2016-01-20 2018-12-11 The Scripps Research Institute ror1 antibody compositions and related methods
WO2018014001A1 (en) 2016-07-14 2018-01-18 Fred Hutchinson Cancer Research Center Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
BR112020002368A2 (en) 2017-08-07 2020-09-01 Nbe-Therapeutics Ag antibody-drug conjugates having high in vivo tolerability

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BASKAR S. ET AL.: "Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia", CLINICAL CANCER RESEARCH, vol. 14, no. 2, 15 January 2008 (2008-01-15), pages 396 - 404, XP009135221, DOI: doi:10.1158/1078-0432.CCR-07-1823 *
FUKUDA T. ET AL.: "Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCE, USA, vol. 105, no. 8, 19 February 2008 (2008-02-19), pages 3047 - 3052, XP009135222, DOI: doi:10.1073/pnas.0712148105 *
KATOH M.: "WNT/PCP signaling pathway and human cancer (review)", ONCOLOGY REPORTS, vol. 14, no. 6, December 2005 (2005-12-01), pages 1583 - 1588, XP009104214 *
MASIAKOWSKI P. AND CARROLL R.D.: "A novel family of cell surface receptors with tyrosine kinase-like domain", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 267, no. 36, 25 December 1992 (1992-12-25), pages 26181 - 26190, XP002266720 *
PAGANONI S. AND FERREIRA A.: "Expression and subcellular localization of Ror tyrosine kinase receptors are developmentially regulated in cultured hippocampal neurons", JOURNAL OF NEUROSCIENCE RESEARCH, vol. 73, 15 August 2003 (2003-08-15), pages 429 - 440 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9938350B2 (en) 2010-06-15 2018-04-10 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
US9523695B2 (en) 2011-01-14 2016-12-20 The Regents Of The University Of California Therapeutic antibodies against ROR-1 protein and methods for use of same
US9933434B2 (en) 2011-01-14 2018-04-03 The Regents Of The University Of California Therapeutic antibodies against ROR-1 protein and methods for use of same
US10627409B2 (en) 2011-01-14 2020-04-21 The Regents Of The University Of California Therapeutic antibodies against ROR-1 protein and methods for use of same
US10900973B2 (en) 2011-01-14 2021-01-26 The Regents Of The University Of California Therapeutic antibodies against ROR-1 protein and methods for use of same
US11536727B2 (en) 2011-01-14 2022-12-27 The Regents Of The University Of California Therapeutic antibodies against ROR-1 protein and methods for use of same
US12222355B2 (en) 2011-01-14 2025-02-11 The Regents Of The University Of California Therapeutic antibodies against ROR-1 protein and methods for use of same
US10344096B2 (en) 2012-08-24 2019-07-09 The Regents Of The University Of California Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
US11312787B2 (en) 2012-08-24 2022-04-26 The Regents Of The University Of California Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
US12162950B2 (en) 2012-08-24 2024-12-10 The Regents Of The University Of California Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
US10688181B2 (en) 2016-06-27 2020-06-23 The Regents Of The University Of California Cancer treatment combinations
US11654193B2 (en) 2016-06-27 2023-05-23 The Regents Of The University Of California Cancer treatment combinations

Also Published As

Publication number Publication date
WO2008103849A4 (en) 2009-01-22
WO2008103849A2 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
WO2008103849A3 (en) Methods and compounds for lymphoma cell detection and isolation
WO2007051077A3 (en) Methods and compounds for lymphoma cell detection and isolation
WO2006076691A3 (en) Irta-2 antibodies and their uses
WO2010063011A3 (en) Methods for the treatment of infections and tumors
WO2008076560A3 (en) Human monoclonal antibodies to btla and methods of use
UA99701C2 (en) HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY Binds TO LIGAND-1 PROGRAMMED CELL DAMAGE (PD-L1)
EA200800094A1 (en) ANTIBODIES CD19 AND THEIR USE
WO2010129609A3 (en) Antibodies and methods of use thereof
WO2008083174A3 (en) Compositions and methods for the treatment of infections and tumors
WO2007133822A8 (en) Gitr antibodies for the treatment of cancer
CL2007003649A1 (en) An anti-cd70 human monoclonal antibody associated molecule conjugate; composition comprising the antibody-associated molecule conjugate; method of inhibiting the growth of tumor cells expressing cd70.
BRPI0618399A2 (en) isolated antigen binding region that is specific for cd38, isolated antibody or a functional fragment thereof that is specific for cd38, isolated antibody or a functional fragment thereof, isolated immunoglobulin, heavy chain variable of an isolated antigen binding region, variable light chain from an isolated antigen binding region, isolated nucleic acid sequence, nucleic acid sequence encoding a variable heavy chain from an isolated antigen binding region, nucleic acid sequence, vector, isolated cell, pharmaceutical composition, use of the pharmaceutical composition, method of inducing specific death of cd38-expressing tumor cells, method of detecting specific death of cd38-expressing tumor cells, method of detecting the presence of cd38 in a minipore source tissue or cell , cd38 detection method in a cd3-expressing erythrocyte 8 and diagnostic composition
EP3530736A3 (en) Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
EP2196474A3 (en) Therapeutic targets in cancer
UA90082C2 (en) SEPARATE MONOCLONAL ANTIBODY OF HUMANS SPECIFICALLY Binding TO CD25 HUMANS AND INHIBITING IL-2 Binding TO CD25
WO2006116181A3 (en) Regulatory t cell mediator proteins and uses thereof
ATE459653T1 (en) MONOCLONAL ANTI-CD71 ANTIBODIES AND THEIR USE FOR TREATING MALIGNANT TUMOR CELLS
TW200833713A (en) Human antibodies that bind CD19 and uses thereof
WO2008019376A3 (en) Compositions and methods using anti-cs1 antibodies to treat multiple myeloma
WO2005097185A3 (en) Irta-5 antibodies and their uses
UA105760C2 (en) Bst2 antibody
WO2008136848A3 (en) Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
WO2010031749A9 (en) Compositions and methods for detecting tlr3
FI20011664A7 (en) Cancer-specific oligosaccharide sequences and their use
RU2011131071A (en) DIAGNOSIS AND TREATMENT OF CANCER BY ANTIBODY AGAINST LGR7

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08730419

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08730419

Country of ref document: EP

Kind code of ref document: A2